AYTU BIOPHARMA, INC Long-term Line of Credit, Noncurrent
AYTU BIOPHARMA, INC (AYTU) had Long-term Line of Credit, Noncurrent of $10.73 million as of 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermLineOfCredit · last filed 2021-05-17
- 2021-03-31: Long-term Line of Credit, Noncurrent $10.73M.
- 2020-06-30: Long-term Line of Credit, Noncurrent $12.87M.
| Period end | Long-term Line of Credit, Noncurrent |
|---|---|
| 2021-03-31 | $10.73M 10-Q · filed 2021-05-17 |
| 2020-06-30 | $12.87M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |